ulcerative colitis
Conditions
Interventions
Control group:Continue using mesalazine at the full dose
Experimental group:Discontinue all mesalazine
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Age 18 to 80 years; 2.Patients diagnosed with ulcerative colitis according to guidelines and without comorbidities such as Crohn's disease or unclassified inflammatory bowel disease; 3.Patients with ulcerative colitis requiring vedolizumab treatment; 4.Patients requiring vedolizumab treatment and concurrently receiving adequate mesalamine; 5.Patients with ulcerative colitis who have achieved remission with vedolizumab treatment; 6.Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of intestinal surgical resection; 2.Patients with a history of vedolizumab use or vedolizumab non-response; 3.Patients with comorbidities requiring vedolizumab treatment; 4.Patients with severe underlying medical conditions who cannot tolerate vedolizumab treatment; 5.Patients who cannot tolerate mesalazine or vedolizumab treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical remission response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endoscopic remission response;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactLu Chao
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed